Study Suggests ChemoFx-Assisted Chemo Reduces Costs
June 4, 2010
A study published in the American Journal of Obstetrics and Gynecology (AJOG) demonstrated the cost savings realized through the use of the ChemoFx Drug Response Marker from Precision Therapeutics for assisting selection of treatment in recurrent ovarian cancer. The study demonstrated that ChemoFx-assisted chemotherapy may result in substantially reduced costs compared with empiric therapy. Learn more about ChemoFx at www.precisiontherapeutics.com.
« Study: BodyMedia Users Lose 3X More Weight | | BodyMedia Featured in Abstracts at ACSM Annual Meeting »
